About this historical patient account: The information below describes reported observations from one case. It does not establish treatment efficacy, safety, a causal relationship or an expected outcome. Outcomes vary, and reported improvement does not demonstrate cure. Do not change prescribed medicines or delay established care based on this account.

Intervention context: This account does not establish that the cell, growth-factor or other biological interventions described are approved or effective for this diagnosis. Some may be investigational. A qualified specialist should explain the current evidence, regulatory status, alternatives, uncertainties and risks before any treatment decision.

Patient Information:

• Name: Mr. Li
• Diagnosis: Type II Diabetes Mellitus
• Date of Birth (D.O.B): August 1, 1956
• Gender: Male
• Country: China

Treatment: Cellular Immune Therapy for Type II Diabetes combined with Nerve Growth Factor Treatment, Physical Therapy, Traditional Chinese Medicine (TCM), and Metabolic Control Management at Beijing Puhua International Hospital (BPIH)

Medical History:
Mr. Li was admitted to BPIH due to Type II Diabetes of eight years duration.

Medical Condition before Cellular Immune Therapy for Type II Diabetes:

• Symptoms:
  • Insulin dependence: injections before meals daily
  • Poor sleep quality
  • Abnormal thirst
  • Nocturia
  • Blurred vision
• Medications:
  • Metformin
  • Phenformin
  • Insulin injections
• Laboratory Results (admission):
  • HbA1c: 9.5%
  • Fasting Blood Glucose (FBG): 14.0 mmol/L (252 mg/dL)
  • Postprandial Blood Glucose (PBG): 25.9 mmol/L (467 mg/dL)

Cellular Immune Therapy for Type II Diabetes:

• Medical protocols applied:
  • Cellular immune therapy described in the historical report; pancreatic islet-cell repair is not established by this case
  • Metabolic function improvement and blood sugar control management
  • Traditional Chinese medicine (TCM)
  • Rehabilitation therapy

Physical Condition after Cellular Immune Therapy for Type II Diabetes (post-therapy):

• Improved laboratory results:
  • HbA1c: 7.6%
  • FBG: 9.4 mmol/L (170 mg/dL) – a decrease of 4.6 mmol/L (82 mg/dL)
  • PBG: 10.0 mmol/L (180 mg/dL) – a decrease of 15.9 mmol/L (287 mg/dL)
• Insulin discontinuation was reported in this historical account; changes to insulin require treating-clinician supervision
• Improved oral medications for blood sugar control only
• Improved sleep quality
• Significant alleviation of symptoms:
  • Abnormal thirst
  • Nocturia
  • Blurred vision

About this historical patient account: The information below describes reported observations from one case. It does not establish treatment efficacy, safety, a causal relationship or an expected outcome. Outcomes vary, and reported improvement does not demonstrate cure. Do not change prescribed medicines or delay established care based on this account.

Intervention context: This account does not establish that the cell, growth-factor or other biological interventions described are approved or effective for this diagnosis. Some may be investigational. A qualified specialist should explain the current evidence, regulatory status, alternatives, uncertainties and risks before any treatment decision.